en · de · es · fr · pt
semax-notes.peptides6579.com › Data › Semax Structure And Research Background — Quick Reference

Semax Structure And Research Background — Quick Reference

By Editorial Desk · published 2026-02-05 · last reviewed 2026-03-14 · Data

neurotrophic factor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-03-14 and is reviewed periodically as new material appears.

Semax Structure and Research Background

Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.

Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.

Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.

Semax Background and Molecular Structure

The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.

Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.

Semax at a glance

PropertyValueNotes
SequenceMet-Glu-His-Phe-Pro-Gly-ProHeptapeptide; ACTH(4-10) analog extended at C-terminus
Molecular mass~813.9 DaFree peptide, unmodified
AppearanceWhite to off-white powderTypical lyophilized solid
SolubilitySoluble in water and salineAlso soluble in common aqueous buffers
Storage (solid)-20 °C, desiccatedProtect from moisture and repeated thawing

研发背景与监管地位

各国监管态度分化明显。俄罗斯按处方药管理,部分东欧国家留有使用记录;欧盟与美国未批准其作为药物上市,市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录,跨境携带则受目的地药品法规约束。

Semax 是人工设计的七肽,序列为 Met-Glu-His-Phe-Pro-Gly-Pro,骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性,同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应,Semax 属于这一路线。鼻内给药是其主要使用方式,俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上,样本规模与终点设置同西方试验惯例存在差异,国际同行对其临床证据的强度看法不一。

Related pages on this site

Notes from published material

Many anatomical terms can be combined to indicate a position in two axes simultaneously or the direction of a movement relative to the body: Anterolateral indicates a position that is both anterior and lateral to the standard anatomical position (such as the bulk of the pectoralis major muscle) or a named organ such as the anterolateral tibial tubercle; anteromedial is used, for example, in the anteromedial central arteries; proximodistal describes the axis of an appendage such as an arm or a leg, taken from its tip at the distal part to where it joins the body at the proximal part. Combined terms were once generally hyphenated, but typically the hyphen is omitted.

== Nomenclature == Family: glycosyltransferases, specifically the hexosyltransferases Systematic name: UDP-galactose D-galactosyltransferase Other names: hydroxylysine galactosyltransferase collagen galactosyltransferase collagen hydroxylysyl galactosyltransferase UDP galactose-collagen galactosyltransferase uridine diphosphogalactose-collagen galactosyltransferase UDPgalactose:5-hydroxylysine-collagen galactosyltransferase Pathway lysine degradation

In enzymology, an aromatic 2-oxoacid reductase (EC 1.1.1.110, previously indolelactate dehydrogenase) is an enzyme that catalyzes the reversible oxidation and reduction of aryllactate compounds to arylpyruvate compounds using the redox cofactor nicotinamide adenine dinucleotide or the similar nicotinamide adenine dinucleotide phosphate. For example, the enzyme may oxidize (R)-3-(4-hydroxyphenyl)lactate to 3-(4-hydroxyphenyl)pyruvic acid.

Toldt's fascia, is a discrete layer of connective tissue containing lymphatic channels. It is found between the two mesothelial layers that separate the mesocolon from the underlying retroperitoneum. It was first described by the Austrian anatomist Carl Toldt (1840–1920) as a fascial plane formed by the fusion of the visceral peritoneum with the parietal peritoneum. This was later called Toldt's fascia.

Sources: en.wikipedia.org

Further detail

Caroxazone (Surodil, Timostenil) is an antidepressant which was formerly used for the treatment of depression but is now no longer marketed. It acts as a reversible monoamine oxidase inhibitor (RIMA) of both MAO-A and MAO-B subtypes, with five-fold preference for the latter.

== 16α-Hydroxylation == Through the action of CYP1A1, CYP1A2, CYP2C8, and the CYP3A isoforms, 16α-hydroxyestradiol (16α-OHE2), also known as estriol, is produced in abundance during pregnancy. 16α-OHE2 can be dehydrogenated to 16α-hydroxyestrone (16α-OHE1), a metabolite that has been shown to bind covalently to the estrogen receptor via Schiff base formation. This covalent linkage occurs between the steroid carbonyl and the ε-amino group of lysine. In theory, 16α-OHE1 could also bind DNA, although this has not been observed. 16α-OHE2 is a potent ER agonist, capable of levels of cellular proliferation stimulation that near those obtained with E2. Though studies in hamster kidney tumor models showed weak carcinogenicity, the carcinogenic potential of 16α-OHE2 in humans remains unknown.

Buserelin, sold under the brand name Suprefact among others, is a medication which is used primarily in the treatment of prostate cancer and endometriosis. It is also used for other indications such as the treatment of premenopausal breast cancer, uterine fibroids, and early puberty, in assisted reproduction for female infertility, and as a part of transgender hormone therapy. In addition, buserelin is used in veterinary medicine. The medication is typically used as a nasal spray three times per day, but is also available for use as a solution or implant for injection into fat. Side effects of buserelin are related to sex hormone deprivation and include symptoms of low testosterone levels and low estrogen levels such as hot flashes, sexual dysfunction, vaginal atrophy, and osteoporosis. Buserelin is a gonadotropin-releasing hormone agonist (GnRH agonist) and works by preventing the production of sex hormones by the gonads. It can lower sex hormone levels by about 95% in both sexes. Buserelin is a peptide and an analogue of GnRHTooltip gonadotropin-releasing hormone. Buserelin was first patented in 1974 and approved for medical use in 1985. It is not available in the United States, but is marketed widely elsewhere in the world, including in the United Kingdom, Canada, and many other countries. The medication is one of only two medically used GnRH analogues that are available as nasal sprays, the other being nafarelin. Buserelin is available as a generic medication.

== Occurrence == Uranium is a naturally occurring element found in low levels in all rock, soil, and water. It is the highest-numbered element found naturally in significant quantities on Earth and is almost always found combined with other elements. Uranium is the 48th most abundant element in the Earth's crust. The decay of uranium, thorium, and potassium-40 in Earth's mantle is thought to be the main source of heat that keeps the Earth's outer core in the liquid state and drives mantle convection, which in turn drives plate tectonics. Uranium's concentration in the Earth's crust is (depending on the reference) 2 to 4 parts per million, or about 40 times as abundant as silver. The Earth's crust from the surface to 25 km (15 mi) down is calculated to contain 1017 kg (2×1017 lb) of uranium while the oceans may contain 1013 kg (2×1013 lb). The concentration of uranium in soil ranges from 0.7 to 11 parts per million (up to 15 parts per million in farmland soil due to use of phosphate fertilizers containing uranium impurities), and its concentration in sea water is 3 parts per billion. Uranium is more plentiful than antimony, tin, cadmium, mercury, or silver, and it is about as abundant as arsenic or molybdenum. Uranium is found in hundreds of minerals, including:

==== Cell-based platform ==== The immune system plays an important role in cancer and can be harnessed to attack cancer cells. Cell-based therapies focus on immunotherapies, mostly by engineering T cells. T cell receptors were engineered and 'trained' to detect cancer epitopes. Chimeric antigen receptors (CARs) are composed of a fragment of an antibody fused to intracellular T cell signaling domains that can activate and trigger proliferation of the cell. Multiple second generation CAR-based therapies have been approved by FDA. Gene switches were designed to enhance safety of the treatment. Kill switches were developed to terminate the therapy should the patient show severe side effects. Mechanisms can more finely control the system and stop and reactivate it. Since the number of T-cells are important for therapy persistence and severity, growth of T-cells is also controlled to dial the effectiveness and safety of therapeutics. Although several mechanisms can improve safety and control, limitations include the difficulty of inducing large DNA circuits into the cells and risks associated with introducing foreign components, especially proteins, into cells.

Sources: en.wikipedia.org

Supporting material

Mick Anglo (born Maurice Anglowitz, 19 June 1916 – 31 October 2011) of Russian Jewish ancestry, was a British comic book writer, editor and artist, as well as an author. He is best known for creating the superhero Marvelman, later known as Miracleman, a character later revived in 1982 in a dark, post-modern reboot by writer Alan Moore, with later contributions by Neil Gaiman. Lisa Appignanesi (born 4 January 1946) writer, novelist, campaigner for free expression; was Chair of the Royal Society of Literature; former President of English PEN; Chair of Freud Museum; chaired 2017 Booker International Prize; Honorary Fellow of St Benet's Hall, Oxford and visiting professor in the Department of English at King's College London, and held a Wellcome Trust; has written for The New York Review of Books, The Guardian and The Observer, as well as making programmes and appearing on the BBC; was Director of Talks and Seminars at the Institute of Contemporary Arts (ICA) in London; was made a Chevalier of the Ordre des Arts et des Lettres and was appointed Officer of the Most Excellent Order of the British Empire (OBE) in the 2013 New Year Honours for services to literature. She became a Fellow of the Royal Society of Literature in 2015 and became the Chair of the Royal Society of Literature Council in 2016. Neal Ascherson (born 5 October 1932) journalist and writer; described by Radio Prague as "one of Britain's leading experts on central and eastern Europe".

==== Blindness and vision impairment ==== Since 2003, researchers have successfully transplanted corneal stem cells into damaged eyes to restore vision. "Sheets of retinal cells used by the team are harvested from aborted fetuses, which some people find objectionable." When these sheets are transplanted over the damaged cornea, the stem cells stimulate renewed repair, eventually restoring vision. The latest such development was in June 2005, when researchers at the Queen Victoria Hospital of Sussex, England were able to restore the sight of forty people using the same technique. The group, led by Sheraz Daya, was able to successfully use adult stem cells obtained from the patient, a relative, or even a cadaver. Further rounds of trials are ongoing.

Portable water purification devices are self-contained, easily transported units used to purify water from untreated sources (such as rivers, lakes, and wells) for drinking purposes. Their main function is to eliminate pathogens, and often also suspended solids and some unpalatable or toxic compounds. These units provide an autonomous supply of drinking water to people without access to clean water supply services, including inhabitants of developing countries and disaster areas, military personnel, campers, hikers, and workers in wilderness, and survivalists. They are also called point-of-use water treatment systems and field water disinfection techniques. Techniques include heat (including boiling), filtration, activated charcoal adsorption, chemical disinfection (e.g. chlorination, iodine, ozonation, etc.), ultraviolet purification (including sodis), distillation (including solar distillation), and flocculation. Often these are used in combination.

Each intervention is evaluated simultaneously at all participating ITP sites using identical experimental protocols, animal husbandry practices, dosing regimens, and outcome measures, ensuring exceptional scientific rigor, reproducibility, and confidence in the results. Research conducted through the ITP has significantly advanced the field of geroscience by identifying interventions that reproducibly increase lifespan and improve measures of healthspan. Investigators evaluate a wide range of compounds and therapeutic strategies targeting key biological mechanisms of aging, including nutrient-sensing pathways, cellular senescence, mitochondrial function, proteostasis, inflammation, oxidative stress, autophagy, stem cell maintenance, and metabolic regulation. In addition to determining effects on longevity, studies assess functional outcomes such as physical performance, metabolic health, cardiovascular function, cognitive performance, cancer incidence, immune function, and age-related pathology. These comprehensive phenotypic assessments provide valuable insights into how interventions influence both lifespan and the quality of aging. The Barshop Institute's extensive aging research infrastructure substantially enhances the capabilities of the Interventions Testing Program.

Sources: en.wikipedia.org

Frequently asked questions

What is semax?

Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.

How is semax related to ACTH?

Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.

Is semax an approved drug?

It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.

What is the amino acid sequence of Semax?

The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.

Network